Further defining the roles and impact of genetic counselors in the biotechnology and pharmaceutical industry
Journal of Genetic Counseling · 2025
DOI: 10.1002/jgc4.1861 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Genetic Counseling, 2025. Verfasst von Emily Maxwell und 3 weiteren Autor:innen. Beteiligte Einrichtung: Genetic Counseling Program, MGH Institute of Health Professions, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Genetic Counseling, Drug Industry, Counselors, Biotechnology. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
As personalized medicine has gained traction, drug development models in the biotechnology and pharmaceutical industry (BPI) have increasingly sought to address medical conditions with a genetic component, creating an opportunity for genetic counselors (GCs) to fill new roles and utilize their unique training to contribute to drug development. Despite the potential for GCs in BPI, literature around the role of GCs in this industry has been limited. Our mixed methods study aimed to assess how the roles of GCs in BPI have evolved since 2016, investigate the value of and opportunity for GCs in this industry, and further characterize their motivation and job satisfaction. Participants were recruited via social media advertising, snowball sampling, and email listservs from the National Society of Genetic Counseling (NSGC), the Canadian Association of Genetic Counselors (CAGC), and the American Board of Genetic Counseling (ABGC). Survey ( n = 20) and interview ( n = 6) data indicates many aspects of GC roles in BPI are consistent with the 2016 study. However, there is evidence of roles becoming more varied and with increasing recognition of the value of GCs, opportunities for involvement in BPI are growing. Furthermore, combined study data found that GCs are motivated by the flexibility of BPI roles as well as the opportunity to contribute to rare disease treatment development and that they are overall satisfied with most aspects of their jobs. Interview data also found that genetic counseling training has the potential to improve clinical trial design and outcomes by making drug development more patient‐centric. Finally, combined study data found that while GCs continue to utilize Accreditation Council of Genetic Counseling (ACGC) practice‐based competencies (PBCs), business‐related training may benefit GCs seeking to enter BPI. Together, these findings are critical for informing genetic counseling training programs, employers within BPI, and GCs interested in entering these positions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genetic Counseling Program, MGH Institute of Health Professions, Boston, Massachusetts, USA.
- Fred Hutchinson Cancer Institute, Seattle, Washington, USA.
- AstraZeneca Pharmaceuticals, One MedImmune Way, Gaithersburg, Maryland, USA.
- Genetic Counseling Program, Indiana State University, Terre Haute, Indiana, USA.
- Spark Therapeutics, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Emily Maxwell
Zitieren
APA
Maxwell, E., Moore, R., Niendorf, K., & Field, T. (2025). Further defining the roles and impact of genetic counselors in the biotechnology and pharmaceutical industry. Journal of Genetic Counseling. https://doi.org/10.1002/jgc4.1861
Vancouver
Maxwell E, Moore R, Niendorf K, Field T. Further defining the roles and impact of genetic counselors in the biotechnology and pharmaceutical industry. Journal of Genetic Counseling. 2025. doi:10.1002/jgc4.1861
BibTeX
@article{Maxwell2025,
author = {Maxwell, Emily and Moore, Rebekah and Niendorf, Kristin and Field, Tessa},
title = {Further defining the roles and impact of genetic counselors in the biotechnology and pharmaceutical industry},
journal = {Journal of Genetic Counseling},
year = {2025},
doi = {10.1002/jgc4.1861}
}
EUVIMED